Pernix Therapeutics Holdings, Inc. (PTX) was a specialty pharmaceutical company that focused on the development and commercialization of prescription drugs for the treatment of central nervous system (CNS) disorders, including insomnia and migraine headaches. The company's product portfolio included Zohydro ER (hydrocodone bitartrate) extended-release capsules, which were used for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and Treximet (sumatriptan and naproxen sodium), which was used for the acute treatment of migraines.
In 2019, Pernix Therapeutics Holdings, Inc. merged with Innovus Pharmaceuticals, Inc. (INNV), a specialty pharmaceutical company that focused on the commercialization of over-the-counter consumer healthcare products and prescription drugs for various medical conditions. The combined company operates under the name Soligenix, Inc. (SNGX), which is focused on developing and commercializing therapies for rare diseases and unmet medical needs.
Pernix Therapeutics Holdings, Inc. (PTX) was a specialty pharmaceutical company that focused on the development and commercialization of prescription drugs for the treatment of central nervous system (CNS) disorders, including insomnia and migraine headaches. The company's product portfolio included Zohydro ER (hydrocodone bitartrate) extended-release capsules, which were used for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and Treximet (sumatriptan and naproxen sodium), which was used for the acute treatment of migraines.